首页> 美国卫生研究院文献>other >Cytotoxicity of Thiazolidinedione- Oxazolidinedione- and Pyrrolidinedione-Ring Containing Compounds in HepG2 Cells
【2h】

Cytotoxicity of Thiazolidinedione- Oxazolidinedione- and Pyrrolidinedione-Ring Containing Compounds in HepG2 Cells

机译:含噻唑烷二酮恶唑烷二酮和吡咯烷二酮环的化合物对HepG2细胞的细胞毒性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Liver damage occurred in some patients who took troglitazone (TGZ) for type II diabetes. The 2,4-thiazolidinedione (TZD) ring in TGZ's structure has been implicated in its hepatotoxicity. To further examine the potential role of a TZD ring in toxicity we used HepG2 cells to evaluate two series of compounds containing different cyclic imides. N-phenyl analogues comprised 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT); 3-(3,5-dichlorophenyl)-2,4-oxazolidinedione (DCPO) and N-(3,5-dichlorophenyl)succinimide (NDPS). Benzylic compounds, which closely resemble TGZ, included 5-(3,5-dichlorophenylmethyl)-2,4-thiazolidinedione (DCPMT); 5-(4-methoxyphenylmethyl)-2,4-thiazolidinedione (MPMT); 5-(4-methoxyphenylmethylene)-2,4-thiazolidinedione (MPMT-I); 5-(4-methoxyphenylmethyl)-2,4-oxazolidinedione (MPMO); 3-(4-methoxyphenylmethyl)succinimide (MPMS) and 3-(4-methoxyphenylmethylene)succinimide (MPMS-I). Cytotoxicity was assessed using the MTS assay after incubating the compounds (0-250 μM) with HepG2 cells for 24 h. Only certain TZD derivatives (TGZ, DCPT, DCPMT and MPMT-I) markedly decreased cell viability, whereas MPMT had low toxicity. In contrast, analogues without a TZD ring (DCPO, NDPS, MPMO, MPMS and MPMS-I) were not cytotoxic. These findings suggest that a TZD ring may be an important determinant of toxicity, although different structural features, chemical stability, cellular uptake or metabolism, etc., may also be involved. A simple clustering approach, using chemical fingerprints, assigns each compound to one of three classes (each containing one active compound and close homologues), and provides a framework for rationalizing the activity in terms of structure.
机译:在因曲格列酮(TGZ)治疗II型糖尿病的某些患者中发生了肝损害。 TGZ结构中的2,4-噻唑烷二酮(TZD)环涉及其肝毒性。为了进一步检查TZD环在毒性中的潜在作用,我们使用了HepG2细胞来评估包含不同环酰亚胺的两个系列化合物。 N-苯基类似物包括3-(3,5-二氯苯基)-2,4-噻唑烷二酮(DCPT); 3-(3,5-二氯苯基)-2,4-恶唑烷二酮(DCPO)和N-(3,5-二氯苯基)琥珀酰亚胺(NDPS)。与TGZ非常相似的苯甲酰基化合物包括5-(3,5-二氯苯基甲基)-2,4-噻唑烷二酮(DCPMT); 5-(4-甲氧基苯基甲基)-2,4-噻唑烷二酮(MPMT); 5-(4-甲氧基苯基亚甲基)-2,4-噻唑烷二酮(MPMT-1); 5-(4-甲氧基苯基甲基)-2,4-恶唑烷二酮(MPMO); 3-(4-甲氧基苯基甲基)琥珀酰亚胺(MPMS)和3-(4-甲氧基苯基甲基)琥珀酰亚胺(MPMS-1)。将化合物(0-250μM)与HepG2细胞孵育24小时后,使用MTS分析评估细胞毒性。仅某些TZD衍生物(TGZ,DCPT,DCPMT和MPMT-1)显着降低细胞活力,而MPMT具有低毒性。相反,没有TZD环的类似物(DCPO,NDPS,MPMO,MPMS和MPMS-1)没有细胞毒性。这些发现表明,尽管也可能涉及不同的结构特征,化学稳定性,细胞摄取或代谢等,但TZD环可能是毒性的重要决定因素。一种简单的聚类方法,使用化学指纹,将每种化合物归为三类(每一种均包含一种活性化合物和紧密的同源物)中的一种,并为根据结构合理化活性提供了框架。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号